Laurus Labs gains on getting USFDA`s tentative approval for Oral Dispersible Film Dolutegravir
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Laurus Labs is currently trading at Rs. 313.45, up by 2.30 points or 0.74% from its previous closing of Rs. 311.15 on the BSE.
The scrip opened at Rs. 312.05 and has touched a high and low of Rs. 313.85 and Rs. 311.60 respectively. So far 15506 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 605.50 on 18-Aug-2022 and a 52 week low of Rs. 279.65 on 28-Apr-2023.
Last one week high and low of the scrip stood at Rs. 317.85 and Rs. 279.65 respectively. The current market cap of the company is Rs. 16760.12 crore.
The promoters holding in the company stood at 27.20%, while Institutions and Non-Institutions held 32.16% and 40.64% respectively.
Laurus Labs has received the United States Food and Drug Administration’s (USFDA) tentative approval for the World’s First Oral Dispersible Film (ODF) Dolutegravir 5mg and 10mg for Pediatric ARV treatment.
This innovative paediatric drug administration through Oral Dispersible Film technology developed by Laurus Labs will simplify the drug administration in children. It will help in bringing a significant benefit in compliance of ARV medication in the paediatric HIV treatment. Laurus Labs was also the first generic approved company for a fixed dose combination of Abacavir/Dolutegravir/Lamivudine 600/50/300 mg, which is being used to treat adult HIV patients for 2nd line treatment.
Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.
